Publicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (10)

2024

  1. Germline assessment for alloHSCT candidates over 50 years: A ‘Fast-Track’ screening in myeloid neoplasms

    British Journal of Haematology, Vol. 205, Núm. 2, pp. 503-509

  2. Recommendations for the future management of thrombocytopenia in patients with liver cirrhosis: A modified RAND/UCLA appropriateness method

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 1, pp. 32-50

2021

  1. A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients

    Blood Cells, Molecules, and Diseases, Vol. 86

  2. Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)

    Scientific Reports

  3. Elucidating the mechanism of action of the attributed immunomodulatory role of eltrombopag in primary immune thrombocytopenia: An in silico approach

    International Journal of Molecular Sciences, Vol. 22, Núm. 13

2019

  1. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia

    Scientific Reports, Vol. 9, Núm. 1

  2. Management of adult patients with primary immune thrombocytopenia (itp) in clinical practice: A consensus approach of the Spanish itp expert group

    Advances in Hematology, Vol. 2019

2014

  1. Proteomic analysis of platelet N-glycoproteins in PMM2-CDG patients

    Thrombosis Research, Vol. 133, Núm. 3, pp. 412-417

2013

  1. GPI-anchor and GPI-anchored protein expression in PMM2-CDG patients

    Orphanet Journal of Rare Diseases, Vol. 8, Núm. 1

2007

  1. The association of the β1-tubulin Q43P polymorphism with intracerebral hemorrhage in men

    Haematologica, Vol. 92, Núm. 4, pp. 513-518